Anticoagulation during and after acute coronary syndrome

Hamostaseologie

Volumn 34, Issue 1, 2014, Pages 72-77

  Ahrens, I ^a   Bode, C ^a   Zirlik, A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ACS; Activated clotting time; Anticoagulation; Bivali rudin; Enoxaparin; Fondaparinux; Heparin; Pegnivacogin; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; PEGNIVACOGIN; PROCOAGULANT; RIVAROXABAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; DISEASE ASSOCIATION; PRACTICE GUIDELINE; TREATMENT DURATION; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; HEMORRHAGE; HUMAN; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84896285338     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-09-0048     Document Type: Article

References (38)

1. Gerdes N, Zirlik A. Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis? Thromb Haemost 2011; 106: 804-813.
2. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004-2013.
3. Brambilla M, Camera M, Colnago D et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and plateletleukocyte aggregates. Arteriosc, Thromb Vasc Biol 2008; 28: 947-953.
4. Viles-Gonzalez JF, Badimon JJ. Atherothrombosis: the role of tissue factor. Int J Biochem Cell Biol 2004; 36: 25-30.
5. Cimmino G, Golino P, Badimon JJ. Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited? Int Emerg Med 2011; 6: 29-34.
6. Edgington TS, Ruf W, Rehemtulla A, Mackman N. The molecular biology of initiation of coagulation by tissue factor. Current studies in hematology and blood transfusion 1991; 58: 15-21.
7. Kopp CW, Gremmel T, Steiner S et al. Plateletmonocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. Platelets 2011; 22: 530-536.
8. Morange PE, Blankenberg S, Alessi MC et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the Athero-Gene study. J Thromb Haemost 2007; 5: 475-482.
9. Eikelboom JW, Mehta SR, Anand SS et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
10. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054.
11. Ahrens I, Smith BK, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology. Expert opinion on drug metabolism & toxicology 2007; 3: 609-620.
12. Höchtl T, Farhan S, Wojta J, Huber K. New anticoagulant agents in acute coronary syndromes. Heart 2011; 97: 244-252.
13. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
14. Chalmers TC, Matta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977; 297: 1091-1096.
15. Magee KD, Campbell SG, Moher D, Rowe BH. Heparin versus placebo for acute coronary syndromes. The Cochrane database of systematic reviews 2008: CD003462.
16. Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms of heparin. Handbook of experimental pharmacology 2012; 207: 43-61.
17. Chew DP, Bhatt DL, LincoffAM et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-966.
18. Tolleson TR, O'Shea JC, Bittl JA et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003; 41: 386-393.
19. Montalescot G, Zeymer U, Silvain J et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011; 378: 693-703.
20. Navarese EP, De Luca G, Castriota F et al. Lowmolecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011; 9: 1902-1915.
21. Murphy SA, Gibson CM, Morrow DA et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007; 28: 2077-2086.
22. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
23. Silvain J, Beygui F, Barthelemy O et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344: e553.
24. Mehta SR, Boden WE, Eikelboom JW et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008; 118: 2038-2046.
25. Montalescot G, Walenga JM. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. Clin Appl Thromb Hemost 2009; 15: 183-196.
26. Steg PG, Jolly SS, Mehta SR et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010; 304: 1339-1349.
27. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
28. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
29. Stone GW, Witzenbichler B, Guagliumi G et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-2204.
30. Meijer A, Verheugt FW, Werter CJ et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 1993; 87: 1524-1530.
31. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
32. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
33. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
34. Stoll P, Bassler N, Hagemeyer CE et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscl Thromb Vascul Biol 2007; 27: 1206-1212.
35. Schwarz M, Meade G, Stoll P et al. Conformationspecific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circulation Res 2006; 99: 25-33.
36. Ahrens I, Bode C. New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors. Current drug discovery technologies 2012; 9: 129-136.
37. Povsic TJ, Vavalle JP, Aberle LH et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 2013; (VOLUME; SEITEN ODER DOI; AUTOR BITTE ERGÄNZEN).
38. Regado, Biosciences, press, release. New Investor Leads Round to Fund Phase 3 Development of REG1. wwwregadobiocom/indexphp/2012/12/regado-biosciences-inc-secures-51-million-seriese-financing/. 2012 December 17.